All In Biotech

Free tool

FAERS Monitor: Xtandi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203415 or its brand name (Xtandi, Enzalutamide). Reports on generic versions are filed under their own applications.

Reports

58,866

Serious

36,319

62% of reports

Hospitalization

11,199

Death reported

11,400

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue10,332
  • death7,715
  • malignant neoplasm progression5,499
  • prostatic specific antigen increased4,361
  • asthenia4,207
  • drug ineffective4,067
  • hot flush3,932
  • decreased appetite3,421
  • nausea3,270
  • dizziness3,172
  • diarrhoea2,813
  • back pain2,307
  • arthralgia2,170
  • underdose2,090
  • fall1,847

Reports by year received

View as table
YearReports
2012244
20132,555
20144,441
20155,923
20167,914
201710,285
20187,756
20193,394
20202,641
20212,409
20222,608
20232,329
20242,508
20252,634
20261,225

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,293 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
prostatic specific antigen increasedSignal4,361164.9159.3486,111
malignant neoplasm progressionSignal5,49920.219.795,503
hot flushSignal3,93219.619.066,045
underdoseSignal2,09010.510.117,505
decreased appetiteSignal3,4215.35.211,973
fatigueSignal10,3324.84.731,763
astheniaSignal4,2074.03.99,653
back painSignal2,3073.63.44,278
deathSignal7,7153.23.212,197
dizzinessSignal3,1722.32.22,320
fall1,8472.01.9916
arthralgia2,1701.91.8889
diarrhoea2,8131.61.5579
nausea3,2701.51.4523
drug ineffective4,0671.11.141

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.